NCT07218913 2026-04-17
Testing the Addition of Pedmark to Cisplatin Chemotherapy for Reducing Drug-Induced Ear Damage in Men With Stage II-III Metastatic Testicular Germ Cell Tumors
City of Hope Medical Center
Phase 1 Recruiting
Clinical Trials
10 trialsNCT06036407 2026-04-14
HEAR
University of Bern
Phase NA Completed
NCT07407582 2026-04-13
Ph. I/II Sodium Thiosulfate for OtoProtection During Cisplatin (STOP-CIS)
University of Arizona
Phase 1/2 Not yet recruiting
NCT06517888 2026-04-06
Anti-VEGF Gene Therapy Trial for Vestibular Schwannoma
Akouos, Inc.
Phase 1/2 Recruiting
NCT04915183 2026-03-09
Atorvastatin to Reduce Cisplatin-Induced Hearing Loss Among Individuals With Head and Neck Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Recruiting
NCT07420751 2026-02-20
Assessment of Patient Experience With Auto-Captioning Glasses in NF2-Related-Schwannomatosis
Massachusetts General Hospital
Phase NA Recruiting
NCT05789316 2026-01-12
Head and Neck Cancer Survivorship Ototoxicity Screening (SOS)
Washington University School of Medicine
Phase NA Completed
NCT05582551 2025-12-22
Patients At Risk for Sensory Screening (HPARSS) to Enhance Sensory Deficit Screening in Childhood Cancer Survivors
Washington University School of Medicine
Phase NA Recruiting
NCT02310399 2025-10-30
Auditory Brainstem Implant (ABI) in Children With No Cochleae or Auditory Nerves
NYU Langone Health
Phase NA Recruiting
NCT06894927 2025-05-30
HSA50+
University Hospital Hradec Kralove
Phase NA Enrolling by invitation